Analysis of Adverse Events of Dasatinib and Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated Outside Clinical Trials

被引：0
|
作者：
Suh, Koung Jin [1 ,2 ]
Lee, Ji Yun [2 ]
Shin, Dong-Yeop [1 ]
Koh, Youngil [1 ]
Bang, Soo-Mee [3 ]
Yoon, Sung-Soo [1 ]
Park, Seonyang [4 ]
Kim, Inho [1 ]
Lee, Jeong-Ok [2 ]
机构：
[1] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea
[2] Seoul Natl Univ Bundang Hosp, Internal Med, Seongnam, South Korea
[3] Seoul Natl Univ Bundang Hosp, Seongnam, South Korea
[4] Inje Univ, Haeundae Paik Hosp, Internal Med, Busan, South Korea
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1902.1902
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1902
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase
    Eskazan, Ahmet Emre
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (03) : 325 - 326
  • [32] Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis
    Adel, Ahmad
    Abushanab, Dina
    Hamad, Anas
    Abdulla, Mohammad
    Izham, Mohamed
    Yassin, Mohamed
    CANCER CONTROL, 2021, 28
  • [33] Long-Term Results and Adverse Events Of Second Line Nilotinib Therapy After Imatinib Failure In Patients With Chronic Myeloid Leukemia In Chronic Phase In Clinical Practice
    Bykova, Anastasia
    Gusarova, Galina
    Chelysheva, Ekaterina Yu
    Turkina, Anna G.
    BLOOD, 2013, 122 (21)
  • [34] Therapeutic adherence of patients to dasatinib or nilotinib with chronic myeloid leukemia in a Belgian University Hospital
    Vermis, K.
    Lesage, D.
    Mertens, S.
    Somers, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (03) : 730 - 731
  • [35] Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
    Hoyle, Martin
    Rogers, Gabriel
    Moxham, Tiffany
    Liu, Zulian
    Stein, Ken
    VALUE IN HEALTH, 2011, 14 (08) : 1057 - 1067
  • [36] An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia
    Muresan, Bogdan
    Mamolo, Carla
    Cappelleri, Joseph C.
    Leip, Eric
    Viqueira, Andrea
    Heeg, Bart
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (05) : 801 - 809
  • [37] Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase
    袁婷
    ChinaMedicalAbstracts(InternalMedicine), 2020, 37 (02) : 111 - 112
  • [38] DASATINIB FRONTLINE IN ELDERLY PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA
    Stagno, F.
    Breccia, M.
    Annunziata, M.
    Trawinska, M.
    Iurlo, A.
    Sgherza, N.
    Fava, C.
    Gozzini, A.
    Luciano, L.
    Bonifacio, M.
    Sora, F.
    Crescenzi, S. Leonetti
    Bocchia, M.
    Crugnola, M.
    Gugliotta, G.
    Capodanno, I.
    Galimberti, S.
    Feo, C.
    Porrini, R.
    Pregno, P.
    Tiribelli, M.
    Rizzo, M.
    Mauro, E.
    Antolino, A.
    Rossi, A. Russo
    Guarini, A.
    Abruzzese, E.
    Vigneri, P.
    Latagliata, R.
    HAEMATOLOGICA, 2017, 102 : 90 - 91
  • [39] Nilotinib and Dasatinib in the First-Line Therapy for chronic myeloid Leukemia
    Pretscher, Dominik
    Wilhelm, Martin
    MEDIZINISCHE KLINIK, 2010, 105 (08) : 588 - 588
  • [40] Vascular Adverse Events During Long-term Nilotinib Therapy in Patients With Chronic Myeloid Leukemia
    Eskazan, Ahmet Emre
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (12): : E63 - E64
12345